CCKB/gastrin receptors mediate changes in sodium and potassium absorption in the isolated perfused rat kidney.
BACKGROUND
To evaluate the function of cholecystokinin B (CCKB)/gastrin receptors in the rat kidney, we identified the receptors by Northern blot and localized the receptors by immunohistochemistry. The functional effects of gastrin were studied under standardized in vitro conditions using the isolated perfused kidney.


METHODS
Rat kidneys were mounted in an organ bath by attaching the renal artery to a perfusion system. A catheter was inserted into the renal vein and the ureter to collect samples that were analyzed for the concentrations of electrolytes. After a preperfusion period, gastrin-17-I was given via the renal artery (10-8 to 10-6 mol/L). Subsequently, hemodynamic parameters (for example, perfusate flow) and changes in sodium and potassium absorption were determined. All data were subjected to a nonparametric analysis of variance and, in case of significant results, to subsequent paired comparisons by the a posteriori Wilcoxon test.


RESULTS
Northern blot analysis detected CCKB receptor transcripts in total RNA isolated from kidneys. Immunohistochemistry localized CCKB receptors on tubules and collecting duct cells. Compared with controls, gastrin (10-6 mol/L) caused a decrease in the fractional sodium reabsorption (basal 80%, 10 minutes after application of gastrin 71%, after 20 minutes 62%, P < 0.05). This effect was inhibited by the CCKB receptor antagonist L-365,260. Gastrin decreased urinary potassium excretion at 10-8 and 10-6 mol/L [maximal decrease at 10-6 mol/L from baseline values (100%) to 49% after 10 minutes and to 69% after 20 minutes, P < 0.05, N = 6]. This effect was also abolished by the CCKB receptor antagonist L-365,260. Gastrin (10-6 mol/L) reduced perfusate flow by 31% (P < 0.05).


CONCLUSIONS
CCKB receptors are expressed in the rat kidney on tubules and collecting ducts. These receptors mediate changes in renal potassium and sodium absorption. In addition, gastrin causes a decrease in perfusate flow, indicating that CCKB receptors might also modulate vascular resistance in the kidney.
von Schrenck
T
T
Department of Medicine, Divisions of Nephrology and Clinical Chemistry, University Hospital Eppendorf, Hamburg, and Institute of Pathology, University of Rostock, Rostock, Germany. schrenck@uke.uni-hamburg.de
Ahrens
M
M
de Weerth
A
A
Bobrowski
C
C
Wolf
G
G
Jonas
L
L
Jocks
T
T
Schulz
M
M
Bläker
M
M
Neumaier
M
M
Stahl
R A
RA
D000818:Animals; D001570:Benzodiazepinones / Q000494:pharmacology; D001692:Biological Transport / Q000187:drug effects / Q000502:physiology; D015152:Blotting, Northern; D005755:Gastrins / Q000494:pharmacology; D015870:Gene Expression / Q000502:physiology; D007150:Immunohistochemistry; D066298:In Vitro Techniques; D007668:Kidney / Q000737:chemistry / Q000378:metabolism*; D008297:Male; D010477:Perfusion; D010671:Phenylurea Compounds / Q000494:pharmacology; D011188:Potassium / Q000378:metabolism*; D012333:RNA, Messenger / Q000032:analysis; D051381:Rats; D017208:Rats, Wistar; D043887:Receptor, Cholecystokinin B; D011949:Receptors, Cholecystokinin / Q000032:analysis / Q000235:genetics / Q000378:metabolism*; D012964:Sodium / Q000378:metabolism*; D014655:Vascular Resistance
D001570:Benzodiazepinones; D005755:Gastrins; D010671:Phenylurea Compounds; D012333:RNA, Messenger; D043887:Receptor, Cholecystokinin B; D011949:Receptors, Cholecystokinin; C058121:L 365260; D012964:Sodium; D011188:Potassium